EXEL Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals has a net margin of 21.87% compared to Exelixis's net margin of -22.27%. Exelixis's return on equity of 20.97% beat Alnylam Pharmaceuticals's return on equity of --.

Exelixis has a consensus price target of $33.56, signalling downside risk potential of -1.2%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $299.11 which suggests that it could grow by 27.67%. Given that Alnylam Pharmaceuticals has higher upside potential than Exelixis, analysts believe Alnylam Pharmaceuticals is more attractive than Exelixis.

Exelixis has a beta of 0.534, which suggesting that the stock is 46.575% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.841%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

Exelixis quarterly revenues are $539.5M, which are larger than Alnylam Pharmaceuticals quarterly revenues of $500.9M. Exelixis's net income of $118M is higher than Alnylam Pharmaceuticals's net income of -$111.6M. Notably, Exelixis's price-to-earnings ratio is 21.78x while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 4.91x versus 14.18x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Incyte has a net margin of 21.87% compared to Exelixis's net margin of 9.36%. Exelixis's return on equity of 20.97% beat Incyte's return on equity of 0.75%.

Exelixis has a consensus price target of $33.56, signalling downside risk potential of -1.2%. On the other hand Incyte has an analysts' consensus of $79.30 which suggests that it could grow by 14%. Given that Incyte has higher upside potential than Exelixis, analysts believe Incyte is more attractive than Exelixis.

Exelixis has a beta of 0.534, which suggesting that the stock is 46.575% less volatile than S&P 500. In comparison Incyte has a beta of 0.706, suggesting its less volatile than the S&P 500 by 29.419%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Incyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Incyte pays out -- of its earnings as a dividend.

Exelixis quarterly revenues are $539.5M, which are smaller than Incyte quarterly revenues of $1.1B. Exelixis's net income of $118M is higher than Incyte's net income of $106.5M. Notably, Exelixis's price-to-earnings ratio is 21.78x while Incyte's PE ratio is 497.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 4.91x versus 3.71x for Incyte. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 21.87% compared to Exelixis's net margin of 18.95%. Exelixis's return on equity of 20.97% beat Merck &'s return on equity of 29.26%.

Exelixis has a consensus price target of $33.56, signalling downside risk potential of -1.2%. On the other hand Merck & has an analysts' consensus of $130.34 which suggests that it could grow by 29.84%. Given that Merck & has higher upside potential than Exelixis, analysts believe Merck & is more attractive than Exelixis.

Exelixis has a beta of 0.534, which suggesting that the stock is 46.575% less volatile than S&P 500. In comparison Merck & has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.989%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.15% to investors and pays a quarterly dividend of $0.81 per share. Exelixis pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

Exelixis quarterly revenues are $539.5M, which are smaller than Merck & quarterly revenues of $16.7B. Exelixis's net income of $118M is lower than Merck &'s net income of $3.2B. Notably, Exelixis's price-to-earnings ratio is 21.78x while Merck &'s PE ratio is 20.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 4.91x versus 3.99x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 21.87% compared to Exelixis's net margin of 7.2%. Exelixis's return on equity of 20.97% beat Sarepta Therapeutics's return on equity of 12.48%.

Exelixis has a consensus price target of $33.56, signalling downside risk potential of -1.2%. On the other hand Sarepta Therapeutics has an analysts' consensus of $185.96 which suggests that it could grow by 47.25%. Given that Sarepta Therapeutics has higher upside potential than Exelixis, analysts believe Sarepta Therapeutics is more attractive than Exelixis.

Exelixis has a beta of 0.534, which suggesting that the stock is 46.575% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.770, suggesting its less volatile than the S&P 500 by 22.964%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Exelixis quarterly revenues are $539.5M, which are larger than Sarepta Therapeutics quarterly revenues of $467.2M. Exelixis's net income of $118M is higher than Sarepta Therapeutics's net income of $33.6M. Notably, Exelixis's price-to-earnings ratio is 21.78x while Sarepta Therapeutics's PE ratio is 82.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 4.91x versus 7.75x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.